# Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction

> **NCT04383262** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Medical College of Wisconsin** · enrollment: 104 (estimated)

## Conditions studied

- Laryngopharyngeal Reflux

## Interventions

- **DRUG:** Fosamprenavir Calcium
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04383262
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-15
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04383262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04383262, "Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04383262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*